Balyasny Asset Management’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-5,404
| Closed | -$745K | – | 3330 |
|
|
2025
Q4 | $745K | Sell |
5,404
-858,229
| -99% | -$112M | ﹤0.01% | 2332 |
|
|
2025
Q3 | $111M | Sell |
863,633
-13,323
| -2% | -$1.63M | 0.14% | 150 |
|
|
2025
Q2 | $106M | Buy |
876,956
+303,553
| +53% | +$34.2M | 0.16% | 141 |
|
|
2025
Q1 | $63.9M | Buy |
573,403
+555,531
| +3,108% | +$59.1M | 0.11% | 240 |
|
|
2024
Q4 | $1.74M | Buy |
+17,872
| New | +$1.91M | ﹤0.01% | 1728 |
|
|
2024
Q3 | – | Sell |
-33,770
| Closed | -$3.6M | – | 3030 |
|
|
2024
Q2 | $3.6M | Buy |
33,770
+21,496
| +175% | +$2.16M | 0.01% | 1322 |
|
|
2024
Q1 | $1.19M | Buy |
12,274
+7,208
| +142% | +$739K | ﹤0.01% | 1713 |
|
|
2023
Q4 | $512K | Buy |
5,066
+1,151
| +29% | +$111K | ﹤0.01% | 1945 |
|
|
2023
Q3 | $399K | Buy |
+3,915
| New | +$397K | ﹤0.01% | 1820 |
|
|
2022
Q1 | – | Sell |
-129,088
| Closed | -$11.3M | – | 2726 |
|
|
2021
Q4 | $11.3M | Buy |
+129,088
| New | +$10.7M | 0.04% | 602 |
|
|
2021
Q1 | – | Sell |
-303,004
| Closed | -$28.6M | – | 1987 |
|
|
2020
Q4 | $28.6M | Buy |
+303,004
| New | +$26.5M | 0.16% | 176 |
|
|
2019
Q3 | – | Sell |
-3,661
| Closed | -$329K | – | 1456 |
|
|
2019
Q2 | $334K | Buy |
+3,661
| New | +$310K | ﹤0.01% | 1299 |
|
|
2019
Q1 | – | Sell |
-262,463
| Closed | -$21.1M | – | 1568 |
|
|
2018
Q4 | $20.2M | Sell |
262,463
-242,841
| -48% | -$18.9M | 0.15% | 196 |
|
|
2018
Q3 | $39M | Buy |
505,304
+112,376
| +29% | +$8.31M | 0.18% | 153 |
|
|
2018
Q2 | $26.6M | Buy |
392,928
+18,748
| +5% | +$1.29M | 0.12% | 234 |
|
|
2018
Q1 | $27.1M | Buy |
374,180
+277,443
| +287% | +$21.1M | 0.11% | 249 |
|
|
2017
Q4 | $7.28M | Sell |
96,737
-163,221
| -63% | -$12.3M | 0.02% | 733 |
|
|
2017
Q3 | $20M | Sell |
259,958
-104,541
| -29% | -$7.9M | 0.08% | 327 |
|
|
2017
Q2 | $27.3M | Buy |
+364,499
| New | +$25.8M | 0.11% | 246 |
|
|
2016
Q4 | – | Sell |
-512,543
| Closed | -$36.3M | – | 1443 |
|
|
2016
Q3 | $36.3M | Buy |
+512,543
| New | +$37.3M | 0.21% | 151 |
|
|
2016
Q1 | – | Sell |
-155,534
| Closed | -$12M | – | 1452 |
|
|
2015
Q4 | $12M | Buy |
+155,534
| New | +$12.4M | 0.08% | 327 |
|
|
2015
Q3 | – | Sell |
-55,800
| Closed | -$4.92M | – | 1315 |
|
|
2015
Q2 | $4.92M | Buy |
+55,800
| New | +$5.12M | 0.03% | 590 |
|
|
2013
Q3 | – | Sell |
-67,518
| Closed | -$4.28M | – | 676 |
|
|
2013
Q2 | $4.28M | Buy |
+67,518
| New | +$4.39M | 0.07% | 323 |
|
Other funds holding NVS
Balyasny Asset Management's NVS Position: Q1 2026 in Review
Balyasny Asset Management sold out of Novartis (NVS) in Q1 2026, closing a stake of 5,404 shares — an estimated $745K sold.
Balyasny Asset Management first reported a position in NVS in Q2 2013 and held it in 23 quarters. The position peaked at $111M in Q3 2025. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.
- Balyasny Asset Management reported no remaining Novartis position as of Q1 2026 after selling out during the quarter.
- Balyasny Asset Management sold 5,404 Novartis shares in Q1 2026, an estimated $745K.
- Balyasny Asset Management first reported a position in Novartis in Q2 2013 and held it in 23 quarters.
- Balyasny Asset Management's Novartis position peaked at $111M in Q3 2025.
- 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.
Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.